[Congressional Record Volume 167, Number 88 (Thursday, May 20, 2021)]
[Senate]
[Page S3256]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1817. Mr. BURR (for himself, Mr. Blunt, and Mr. Risch) submitted 
an amendment intended to be proposed by him to the bill S. 1260, to 
establish a new Directorate for Technology and Innovation in the 
National Science Foundation, to establish a regional technology hub 
program, to require a strategy and report on economic security, 
science, research, innovation, manufacturing, and job creation, to 
establish a critical supply chain resiliency program, and for other 
purposes; which was ordered to lie on the table; as follows:

       At the appropriate place, insert the following:

     SEC. __. UNITED STATES EMERGENCY PLAN FOR COVID-19 VACCINES.

       (a) In General.--The Secretary of State shall, as 
     appropriate, provide assistance to prevent, mitigate, and 
     respond to the COVID-19 pandemic through the purchase and 
     delivery of vaccines to regions or countries affected by, or 
     at risk of, COVID-19. The Secretary--
       (1) may provide such assistance through existing bilateral 
     or multilateral agreements;
       (2) shall maximize public-private partnerships in the 
     purchase and delivery of such vaccines; and
       (3) shall furnish such assistance, consistent with 
     subsection (b) and on such terms as the Secretary may 
     determine, to support global health security and to prevent 
     and mitigate the spread of COVID-19.
       (b) Requirements.--As a condition of receipt of vaccines 
     provided for under this section, a country shall commit to 
     uphold intellectual property protections related to COVID-19 
     vaccines under the Agreement on Trade-Related Aspects of 
     Intellectual Property Rights of the World Trade Organization.
       (c) Consultation.--The Secretary of State shall, as 
     appropriate, consult with the Secretary of Health and Human 
     Services in carrying out this section.
       (d) Clarification.--The United States Trade Representative 
     shall not approve any measure to waive provisions of the 
     Agreement on Trade-Related Aspects of Intellectual Property 
     Rights protecting intellectual property rights related to 
     COVID-19 vaccines provided under this section.
       (e) Authorization of Appropriations.--There is authorized 
     to be appropriated to carry out this section, $25,000,000,000 
     for fiscal year 2021, to remain available until September 30, 
     2024.
                                 ______